These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 2574044)

  • 1. Hemodynamic and endocrinological effects of a new selective alpha 1-blocking agent, terazosin, in patients with essential hypertension. Results of long-term treatment.
    Tomoda F; Takata M; Yoshida K; Yasumoto K; Mikawa M; Sasayama S
    Am J Hypertens; 1989 Nov; 2(11 Pt 1):834-9. PubMed ID: 2574044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversal of left ventricular hypertrophy by terazosin in hypertensive patients.
    Yasumoto K; Takata M; Yoshida K; Mikawa M; Tomoda F; Sasayama S
    J Hum Hypertens; 1990 Feb; 4(1):13-8. PubMed ID: 1971654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular effects of short-term selective alpha 1-adrenergic blockade with terazosin in patients with essential hypertension.
    Beretta-Piccoli C; Ferrier C; Weidmann P
    J Hypertens Suppl; 1985 Dec; 3(3):S231-4. PubMed ID: 2908818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Terazosin: a new alpha adrenoceptor blocking drug.
    Achari R; Laddu A
    J Clin Pharmacol; 1992 Jun; 32(6):520-3. PubMed ID: 1353083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Terazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in essential hypertension.
    Titmarsh S; Monk JP
    Drugs; 1987 May; 33(5):461-77. PubMed ID: 2885169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Terazosin, a new selective alpha 1-adrenergic blocking agent. Results of long-term treatment in patients with essential hypertension.
    Luther RR; Glassman HN; Estep CB; Schmitz PJ; Horton JK; Jordan DC
    Am J Hypertens; 1988 Jul; 1(3 Pt 3):237S-240S. PubMed ID: 2901267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alpha 1-blockade for the treatment of hypertension: a megastudy of terazosin in 2214 clinical practice settings.
    Itskovitz HD
    Clin Ther; 1994; 16(3):490-504. PubMed ID: 7923316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Terazosin: a new alpha 1-blocker for the treatment of hypertension: a review of randomized, controlled clinical trials of once-daily administration as monotherapy.
    Luther RR; Glassman HN; Sperzel WD; Steinberg FJ; Horton JK; Jordan DC
    J Hypertens Suppl; 1986 Dec; 4(5):S494-7. PubMed ID: 2883273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alpha-1-adrenergic blockade and lipoprotein metabolism in essential hypertension.
    Ferrier C; Beretta-Piccoli C; Weidmann P; Mordasini R
    Clin Pharmacol Ther; 1986 Nov; 40(5):525-30. PubMed ID: 2876796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of antihypertensive and lipid actions of terazosin and atenolol in essential hypertension.
    Silke B; Guy S; Humphreys JE
    J Hum Hypertens; 1992 Jun; 6(3):221-5. PubMed ID: 1352828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multicentre, hospital study of the efficacy and safety of terazosin and its effects on the plasma cholesterol levels of patients with essential hypertension.
    Lytle TB; Coles SJ; Waite MA
    J Clin Pharm Ther; 1991 Aug; 16(4):263-73. PubMed ID: 1682328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alpha 1-adrenergic blockade and cardiovascular pressor responses in essential hypertension.
    Beretta-Piccoli C; Ferrier C; Weidmann P
    Hypertension; 1986 May; 8(5):407-14. PubMed ID: 2870984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antihypertensive dose-response relationships: studies with the selective alpha 1-blocking agent terazosin.
    Weber MA; Cheung DG; Laddu AR; Luther RR
    Am Heart J; 1991 Sep; 122(3 Pt 2):905-10. PubMed ID: 1678921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of oral and intravenous terazosin and head-up tilt on blood pressure responses in patients with hypertension.
    Achari R; Hosmane B; Linnen P; Cavanaugh J; Baroldi P; Cohen A
    J Clin Pharmacol; 1998 Jun; 38(6):545-53. PubMed ID: 9650545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of the renin-angiotensin system in the development of hemodynamic and clinical tolerance to long-term prazosin therapy in patients with severe chronic heart failure.
    Packer M; Medina N; Yushak M
    J Am Coll Cardiol; 1986 Mar; 7(3):671-80. PubMed ID: 2869077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term therapy with terazosin may improve glucose and lipid metabolism in hypertensives: a multicenter prospective study.
    Shionoiri H; Gotoh E; Ito T; Hata T; Iwatsubo H; Takegawa K; Ogihara T; Mikami H; Ikegami H; Otsuka A
    Am J Med Sci; 1994 Feb; 307 Suppl 1():S91-5. PubMed ID: 7908168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Terazosin: a new antihypertensive agent with favorable effects on lipids.
    Luther RR
    Int J Clin Pharmacol Ther Toxicol; 1989 Jul; 27(7):313-9. PubMed ID: 2570758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of terazosin in the treatment of essential hypertension in blacks.
    Luther RR; Klepper MJ; Maurath CJ; Glassman HN; Achari R; Laddu AR
    J Hum Hypertens; 1990 Apr; 4(2):151-3. PubMed ID: 1971027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alpha-adrenergic receptor blockade with prazosin. Consideration of hypertension, heart failure, and potential new applications.
    Colucci WS
    Ann Intern Med; 1982 Jul; 97(1):67-77. PubMed ID: 6124197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term efficacy and safety of terazosin alone and in combination with other antihypertensive agents.
    Cohen JD
    Am Heart J; 1991 Sep; 122(3 Pt 2):919-25. PubMed ID: 1678923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.